ArticleLung cancer (Amsterdam, Netherlands)2016
Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.
Article in Lung cancer (Amsterdam, Netherlands), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 67 citations in OpenAlex.
- Lung Cancer Screening in Cancer Survivors vs Those Without a History of Cancer.JAMA network open · 2025Article
- Proposal of Modified Lung-RADS in Assessing Pulmonary Nodules of Patients with Previous Malignancies: A Primary Study.Diagnostics (Basel, Switzerland) · 2023Article
- Survival in non-small cell lung cancer patients with versus without prior cancer.Scientific reports · 2023Article
- Is prior cancer history a hindrance for non-small cell lung cancer patients to participate in clinical trials?BMC cancer · 2023Article
- Prognosis of male lung cancer patients with urinary cancer: a study from a national population-based analysis.Scientific reports · 2023Article
- Risk and prognosis of secondary bladder cancer after post-operative radiotherapy for gynecological cancer.Bosnian journal of basic medical sciences · 2022Article
- Effect of prior cancer history on survival of patients with esophageal carcinoma: a propensity score matching, population-based study.Journal of thoracic disease · 2022Article
- Lung Cancer Computational Biology and Resources.Cold Spring Harbor perspectives in medicine · 2022Review
- Increased risk of secondary bladder cancer after radiation therapy for endometrial cancer.Scientific reports · 2022Article
- Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer.BioMed research international · 2022Article
- Lung Cancer Screening With Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- Article
- Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria.BMC cancer · 2021Article
- Survival outcomes in prostate cancer patients with a prior cancer.Translational andrology and urology · 2021Article
- The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer.Frontiers in oncology · 2021Article
- Previous Extrapulmonary Malignancies Impact Outcomes in Patients With Surgically Resected Lung Cancer.Frontiers in surgery · 2021Article
- Article
- Observational
- Prognosis of Hepatocellular Carcinoma Among Cancer Survivors with Other Types of Primary Tumors.Digestive diseases and sciences · 2020Article
- Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score-Adjusted, Population-Based Study.Cancer research and treatment · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
introductionManagement of locally advanced non-small cell lung cancer is among the most highly contested areas in thoracic oncology. In this population, a history of prior cancer frequently results in exclusion from clinical trials and may influence therapeutic decisions. We therefore determined prevalence and prognostic impact of prior cancer among these patients. MATERIALS AND
methodsWe identified patients>65years of age diagnosed 1992-2009 with locally advanced lung cancer in the Surveillance, Epidemiology, and End Results-Medicare linked dataset. We characterized prior cancer by prevalence, type, stage, and timing. We compared all-cause and lung cancer-specific survival between patients with and without prior cancer using propensity score-adjusted Cox regression.
results51,542 locally advanced lung cancer patients were included; 15.8% had a history of prior cancer. Prostate (25%), gastrointestinal (17%), breast (16%), and other genitourinary (15%) were the most common types of prior cancer, and 76% percent of prior cancers were localized or in situ stage. Approximately half (54%) of prior cancers were diagnosed within 5 years of the index lung cancer date. Patients with prior cancer had similar (propensity-score adjusted hazard ratio [HR] 0.96; 95% CI, 0.94-0.99; P=0.005) and improved lung cancer-specific (HR 0.84; 95% CI, 0.81-0.86; P<0.001) survival compared to patients with no prior cancer.
conclusionsFor patients with locally advanced lung cancer, prior cancer does not adversely impact clinical outcomes. Patients with locally advanced lung cancer and a history of prior cancer should not be excluded from clinical trials, and should be offered aggressive, potentially curative therapies if otherwise appropriate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.